Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for rare bone cancer: drug combo trial targets toughest cases

NCT ID NCT05830084

First seen Jan 08, 2026 · Last updated Apr 30, 2026 · Updated 14 times

Summary

This early-stage trial tests whether adding the targeted drug regorafenib to standard chemotherapy is safe for people with newly diagnosed, widespread Ewing sarcoma. The study enrolls about 23 patients aged 2 to 49 whose cancer has spread beyond the lungs. The main goal is to find the right dose and check for serious side effects, with the hope of improving outcomes for this hard-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, France

  • Centre Oscar Lambret

    Lille, France

  • Gustave Roussy

    Villejuif, Île-de-France Region, 94805, France

  • Institut Curie

    Paris, France

  • Istituto Nazionale dei Tumori

    Milan, 20133, Italy

  • Monash Children's Hospital

    Clayton, Australia

  • Perth Children's Hospital

    Perth, WA6009, Australia

  • Princess Máxima Center

    Utrecht, 113, Netherlands

  • Queensland Children's Hospital

    Brisbane, Australia

  • Rigshospitalet

    Copenhagen, DK-2100, Denmark

  • Royal Children's Hospital

    Parkville, Australia

  • Vall d'Hebron University Hospital

    Barcelona, 119-12, Spain

  • centre Léon Bérard

    Lyon, France

Conditions

Explore the condition pages connected to this study.